Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash from Financing Activities (2016 - 2025)

Iradimed (IRMD) has disclosed Cash from Financing Activities for 13 consecutive years, with -$10.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 349.78% to -$10.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$17.6 million through Dec 2025, down 22.77% year-over-year, with the annual reading at -$17.6 million for FY2025, 22.77% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$10.9 million at Iradimed, down from -$2.2 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $54154.0 in Q3 2021, with the low at -$13.3 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is -$2.9 million, with a median of -$1.1 million recorded in 2023.
  • The sharpest move saw Cash from Financing Activities soared 101.7% in 2021, then crashed 34536.13% in 2022.
  • Over 5 years, Cash from Financing Activities stood at $2157.0 in 2021, then crashed by 9300.6% to -$198457.0 in 2022, then crashed by 32.32% to -$262590.0 in 2023, then tumbled by 820.64% to -$2.4 million in 2024, then tumbled by 349.78% to -$10.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$10.9 million, -$2.2 million, and -$2.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.